Aflibercept 8 mg accepted by FDA for priority review for the treatment of wet AMD and DME
FDA has accepted for priority review the Biologics License Application (BLA
LEARN MORELearn about innovations, breakthrough discoveries, research and new technologies in the field of retina.
FDA has accepted for priority review the Biologics License Application (BLA
LEARN MOREThe first symposium of IVEG Controversies on Intravitreal Therapies
LEARN MOREIn the CENTERA study, significant functional and anatomic improvements were
LEARN MOREHome monitoring, intravitreal treatments, gene therapy, AI. The future of ophthalmology through the
LEARN MOREError